Ara Parseghian Medical Research Foundation
A Goal For Life
The Faces of NPC
Quote from ara
Video 1




ND Cycling Team raising money

YouTube-Celebrating Ara's 90th B'Day

Survivor Tales
Legacy of Hope part 1

Legacy of Hope part 2

University of Notre Dame: Fighting For The Lives Of Children

See More Videos

Niemann-Pick Type C is a genetic, cholesterol storage disorder that primarily strikes children with death occurring before or during adolescence. There is also an adult onset form of the disease.

 The Ara Parseghian Medical Research Foundation is a non-profit organization dedicated to funding medical research projects to find a treatment for Niemann-Pick Type C (NP-C) disease. The Parseghian Foundation is named in honor of Ara Parseghian, the much beloved and well-known Notre Dame Football Coach, whose three youngest grandchildren were diagnosed with NP-C in 1994. 

Medical research is the key to saving the lives of all those around the world afflicted with Niemann-Pick disease. You can help by donating to the Ara Parseghian Medical Research Foundation. Thank you.

Donate Now

Upcoming EventsJune 4-7, 2016
The annual Parseghian Scientific Conference” for Niemann-Pick Type C

Read MoreRead  More

APMRF Newsletter

A Goal for Life - The Newsletter of the Ara Parseghian Medical Research Foundation.

Read MoreRead More


A Message from Ara

Our hearts are broken. The pain of losing our three youngest grandchildren is almost unbearable.

Ara Message
Read MoreRead More




Jim Click 2015 Mustang Raffle

Jim Click automotive Team presents the 2015 Ford Mustang, 50th Anniversary Edition Raffle. With your $25 contribution (or 5 tickets for $100) you could win a 2015 Ford Mustang, 50th Anniversary Edition, valued at approximately $46,995. For those who purchase tickets from the Ara Parseghian Foundation, you will also be entered into the Parseghian Foundation Give-Away. Click here for an order form OR click here to purchase tickets online.

September 28, 2015


Vtesse, Inc. Initiates Phase 2b/3 Clinical Trial of VTS-270 for Treatment of Niemann Pick Type C1 (NPC) Disease

  •  During its first year of operations, Vtesse advances lead program into late-stage, pivotal trial and launches

  • Goal is to establish a clear foundational data set on the safety and efficacy of VTS-270 for treatment of NPC  

Gaithersburg, MD, September 28, 2015 – Vtesse, Inc. today announced that the first three patients have been screened for inclusion in its pivotal Phase 2b/3 clinical trial with VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC). This clinical trial follows a Phase 1 study conducted by researchers at the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).


Read More


Helping KidsSadly, the Parseghian family has lost Michael, Marcia and Christa to Niemann-Pick Type C disease.  Their hearts will be forever broken.

Their resolve, however, to continue the fight against NP-C disease is not broken.  The Parseghians and thousands of volunteers and friends across the US and around the world are raising funds and pushing medical research so that a treatment can be found.

Please help us in this valiant effort so that everyone afflicted with Niemann-Pick around the world can live to realize their hopes and dreams. Thank you.


Hope for KidsWe Need Your Help!
.Angel Twins
.BReaK Thru Fund
.Fight For Jessica
.Help Kevin
.Hadley Hope
.See More >>


© 2008 Ara Parseghian Medical Research Foundation
Mailing Address: 4729 E Sunrise Dr. #327, Tucson, Arizona 85718-4535,

Phone: (520) 577-5106 Fax: (520) 577-5212, E-Mail: